Mutational spectrum of the NF2 gene: A meta-analysis of 12 years of research and diagnostic laboratory findings

Human Mutation

Volumn 28, Issue 1, 2007, Pages 1-12

  Ahronowitz, Iris ^a   Xin, Winnie ^a   Kiely, Rosemary ^a   Sims, Katherine ^a   MacCollin, Mia ^a   Nunes, Fabio P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Meningioma; Neurofibromatosis; NF2; Schwannoma; Tumor suppressor gene

Indexed keywords

CANCER INHIBITION; CHROMOSOME 22; CHROMOSOME REARRANGEMENT; CLINICAL STUDY; CLINICAL TRIAL; DNA FLANKING REGION; EXON; FRAMESHIFT MUTATION; GENE CLUSTER; GENE DELETION; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MENINGIOMA; MUTATIONAL ANALYSIS; NEURILEMOMA; NEUROFIBROMATOSIS; NONSENSE MUTATION; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

CYTOGENETIC ANALYSIS; GENES, NEUROFIBROMATOSIS 2; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33845946249     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20393     Document Type: Review

References (107)

1. Agbi M, Kluwe L, Webster M, Jacoby L, Barker F, Ojemann R, Mautner VF, MacCollin M. 2006. Unilateral vestibular schwannoma with other NF2-related tumors: clinical and molecular study of a unique phenotype. J Neurosurg 104:201-207.
2. Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. 2000. Population-based analysis of sporadic and type 2 neurofibromatosis- associated meningiomas and schwannomas. Neurology 54:71-76.
3. Baser ME, Kluwe L, Mautner VF. 1999. Germ-line NF2 mutations and disease severity in neurofibromatosis type 2 patients with retinal abnormalities. Am J Hum Genet 64:1230-1233.
4. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. 2002a. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765.
5. Baser ME, Makariou EV, Parry DM. 2002b. Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217-222.
6. Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lazaro C, Joncourt F, Parry DM, Rouleau GA, Evans DG. 2005. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 42:540-546.
7. Baser ME and the Contributors to the International NF2 Mutation Database. 2006. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27:297-306.
8. Bian LG, Tirakotai W, Sun QF, Zhao WG, Shen JK, Luo QZ. 2005. Molecular genetics alterations and tumor behavior of sporadic vestibular schwannoma from the People's Republic of China. J Neurooncol 73:253-260.
9. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ, Testa JR. 1995. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854-10858.
10. Bourn D, Carter SA, Mason S, Gareth D, Evans R, Strachan T. 1994. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet 3:813-816.
11. Bourn D, Evans G, Mason S, Tekes S, Trueman L, Strachan T. 1995. Eleven novel mutations in the NF2 tumour suppressor gene. Hum Genet 95:572-574.
12. Bruder CE, Hirvela C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluwe L, Mautner V, Sainio M, Hung G, Mathiesen T, Moller C, Pulst SM, Harder H, Heiberg A, Honda M, Niimura M, Sahlen S, Blennow E, Albertson DG, Pinkel D, Dumanski JR 2001. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 10:271-282.
13. Chen HJ, Teng HC, Li SS. 1998. Molecular characterization of germline mutations in neurofibromatosis 2 in two families. J Formos Med Assoc 97:869-872.
14. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. 1999. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 24:238-242.
15. Claudio JO, Marineau C, Rouleau GA. 1994. The mouse homologue of the neurofibromatosis type 2 gene is highly conserved. Hum Mol Genet 3:185-190.
16. DeAngelis LM. 2001. Brain tumors. N Engl J Med 344:114-123.
17. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, Montait E, Papi L. 1996. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet 97:632-637.
18. den Bakker MA, Vissers KJ, Molijn AC, Kros JM, Zwarthoff EC, van der Kwast TH. 1999. Expression of the neurofibiomatosis type 2 gene in human tissues. J Histochem Cytochem 47:1471-1480.
19. Diaz de Stahl T, Hansson CM, Bustos C, Mantripragada KK, Piotrowski A, Benetkiewicz M, Jarbo C, Wiklund L, Mathiesen T, Nyberg G, Collins VP, Evans DG, Ichimura K, Dumanski JR 2005. High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. Hum Genet 118:35-44.
20. Ebert C, von Haken M, Meyer-Puttlitz B, Wiestier OD, Reifenberger G, Pietsch T, von Deimling A. 1999. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 155:627-632.
21. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R. 1992. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841-846.
22. Evans DG, Mason S, Huson SM, Ponder M, Harding AE, Strachan T. 1997. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry 62:361-366.
23. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. 1998. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 35:450-455.
24. Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, Golubic M. 2001. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 94:111-117.
25. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005a. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93-97.
26. Evans DG, Watson C, King A, Wallace AJ, Baser ME. 2005b. Multiple meningiomas: differential involvement of the NF2 gene in children and adults. J Med Genet 42:45-48.
27. Evans DG, Maher ER, Baser ME. 2005c. Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. J Med Genet 42:630-632.
28. Fukasawa T, Chong JM, Sakurai S, Koshiishi N, Ikeno R, Tanaka A, Matsumoto Y, Hayashi Y, Koike M, Fukayama M. 2000. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 91:1241-1249.
29. Gautreau A, Fievet BT, Brault E, Antony C, Houdusse A, Louvard D, Arpin M. 2003. Isolation and characterization of an aggresome determinant in the NF2 tumor suppressor. J Biol Chem 278:6235-6242.
30. Gonzalez-Agosti C, Xu L, Pinney D, Beauchamp R, Hobbs W, Gusella J, Ramesh V. 1996. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13:1239-1247.
31. Gutmann DH, Hirbe AC, Haipek CA. 2001. Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet 10:1519-1529.
32. Haase VH, Trofatter JA, MacCollin M, Tarttelin E, Gusella JF, Ramesh V. 1994. The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms. Hum Mol Genet 3:407-411.
33. Hansson CM, Ali H, Bruder CE, Fransson I, Kluge S, Andersson B, Roe BA, Menzel U, Dumanski JP. 2003. Strong conservation of the human NF2 locus based on sequence comparison in five species. Mamm Genome 14:526-536.
34. Heinrich B, Hartmann C, Stemmer-Rachamimov AO, Louis DN, MacCollin M. 2003. Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer 103:483-488.
35. Heth JA, Kirby P, Menezes AH. 2000. Intraspinal familial clear cell meningioma in a mother and child. Case report. J Neurosurg 93:317-321.
36. Hung G, Faudoa R, Baser ME, Xue Z, Kluwe L, Slattery W, Brackman D, Lim D. 2000. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas. Cancer Genet Cytogenet 118:167-168.
37. Ikeda T, Hashimoto S, Fukushige S, Ohmori H, Horii A. 2005. Comparative genomic hybridization and mutation analyses of sporadic schwannomas. J Neurooncol 72:225-230.
38. International HapMap Consortium. 2005. A haplotype map of the human genome. Nature 437:1299-1320.
39. Irving RM, Monat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER. 1994. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 3:347-350.
40. Irving RM, Harada T, Moffat DA, Hardy DG, Whittaker JL, Xuereb JH, Maher ER. 1997. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma. Am J Otol 18:754-760.
41. Jacoby LB, MacCollin M, Louis DN, Mohney T, Rubio MP, Pulaski K, Trofatter JA, Kley N, Seizinger B, Ramesh V, Gusella J. 1994. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 3:413-419.
42. Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF. 1996. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromsomes Cancer 17:45-55.
43. Jacoby LB, Jones D, Davis K, Kronn D, Short MP, Gusella J, MacCollin M. 1997. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 61:1293-1302.
44. Jacoby LB, MacCollin M, Parry DM, Kluwe L, Lynch J, Jones D, Gusella JF. 1999. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics 2:101-108.
45. Joachim T, Ram Z, Rappaport ZH, Simon M, Schramm J, Wiestler OD, von Deimling A. 2001. Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer 94:218-221.
46. Kaufman DL, Heinrich BS, Willett C, Perry A, Finseth F, Sobel RA, MacCollin M. 2003. Somatic instability of the NF2 gene in schwannomatosis. Arch Neurol 60:1317-1320.
47. Kazakov DV, Pitha J, Sima R, Vanecek T, Shelekhova K, Mukensnabl P, Michal M. 2005. Hybrid peripheral nerve sheath tumors: Schwannoma-perineurioma and neurofibroma-perineurioma. A report of three cases in extradigital locations. Ann Diagn Pathol 9:16-23.
48. Kehrer-Sawatzki H, Udart M, Krone W, Baden R, Fahsold R, Thomas G, Schmucket B, Assum G. 1997. Mutational analysis and expression studies of the neurofibromatosis type 2 (NF2) gene in a patient with a ring chromosome 22 and NF2. Hum Genet 100:67-74.
49. Kluwe L, Mautner VF. 1996. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 97:224-227.
50. Kluwe L, Bayer S, Baset ME, Hazim W, Haase W, Funsterer C, Mautner VF. 1996. Identification of NF2 germ-line mutations and comparison with neurofibtomatosis 2 phenotypes. Hum Genet 98:534-538.
51. Kluwe L, Mautner VF. 1998. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 7:2051-2055.
52. Kluwe L, Mautner V, Parry DM, Jacoby LB, Baser M, Gusella J, Davis K, Stavrou D, MacCollin M. 2000. The parental origin of new mutations in neurofibromatosis 2. Neurogenetics 3:17-24.
53. Kluwe L, Mautnet V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. 2003. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40:109-114.
54. Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M, Mautnet V. 2005. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer 42:384-391.
55. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
56. Kressel M, Schmucker B. 2002. Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum Mol Genet 11:2269-2278.
57. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E. 2001. NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367 372.
58. Lamszus K, Lachenmayer L, Heinemann U, Kluwe L, Finckh U, Hoppner W, Stavrou D, Fillbrandt R, Westphal M. 2001. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 91:803-808.
59. Lasota J, Fetsch JF, Wozniak A, Wasag B, Sciot R, Miettinen M. 2001. The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases. Am J Pathol 158:1223-1229.
60. Legoix P, Legrand MF, Ollagnon E, Lenoir G, Thomas G, Zucman-Rossi J. 1999. Characterisation of 16 polymorphic markers in the NF2 gene: application to hemizygosity detection. Hum Mutat 13:290-293.
61. Leondi A, Valotassiou V, Koutsikos J, Tsiouris S, Mainta E, Zerva C. 2005. Multiple meningiomas. Clin Nucl Med 30:361-362.
62. Leone PE, Bello MJ, Mendiola M, Vaquero J, Sarasa JL, Kusak ME, De Campos JM, Pestana A, Rev JA. 1998. Six novel mutations in the NF2 tumor suppressor gene. Int J Oncol 12:935-938.
63. Leverkus M, Kluwe L, Roll EM, Becker G, Brocker EB, Mautner VF, Hamm H. 2003. Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis? Br J Dermatol 148:804-809.
64. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, Aminoso C, de Campos JM, Isla A, Vaquero J, Rey JA. 2005. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42:314-319.
65. MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. 1993. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA 270:2316-2320.
66. MacCollin M, Ramesh V, Jacohy LB, Louis DN, Rubio MP, Pulaski K, Trofattet JA, Short MP, Bove C, Eldridge R, Parry DM, Gusella JF. 1994. Mutational analysis of patients with neurofibromarosis 2. Am J Hum Gener 55:314-320.
67. MacCollin M, Willett C, Heinrich B, Jacoby LB, Acierno JS, Jr. Perry A, Louis DN. 2003. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology 60:1968-1974.
68. Mautner VF, Lindenau M, Baser ME, Hazim W, Taragiba M, Haase W, Samii M, Wais R, Pulst SM. 1996. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38:880-885.
69. Maxwell M, Shih SD, Galanopaulos T, Hedley-Whyte ET, Cosgrove GR. 1998. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases. J Neurosurg 88:562-569.
70. McClatchey AI, Giovannini M. 2005. Membrane organization and tumorigenesis the NF2 tumor suppressor, Merlin. Genes Dev 19:2265-2277.
71. McDowell JR. 1990. Familial meningioma. Neurology 40:312-314.
72. Merel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, Moisan JP, Resche F, Nishisho I, Estivill X, Delattre JY, Poisson M, Theillet C, Hulsebos T, Delattre O, Thomas G. 1995. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13:211-216.
73. Mohyuddin A, Neary WJ, Wallace A, Wu CL, Purcell S, Reid H, Ramsden RT, Read A, Black G, Evans DG. 2002. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 39:315 322.
74. Mohyuddin A, Baser ME, Watson C, Putcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DG. 2003. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 40:459-463.
75. Nakasu S, Hirano A, Shimura T, Llena JF. 1987. Incidental meningiomas in autopsy study. Surg Neurol 27:319-322.
76. Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, Huang DP. 1995. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 37:764-773.
77. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J, MacCollin M. 2005. Inactivation patterns of NF2 and DAL-1/4-1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162:135-139.
78. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. 1994. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450-461.
79. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. 1996. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 59:529-539.
80. Pearson WR. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. Methods Enzymol 183:63-98.
81. Pineau P, Marchio A, Nagamori S, Seki S, Tiollais P, Dejean A. 2003. Homozygous deletion scanning in hepatobiliary tumor cell lines reveals alternative pathways for liver carcinogenesis. Hepatology 37:852-861.
82. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP. 1993. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 43:2096-2098.
83. Rouleau GA, Merel R Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Leioir G, Biljsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-521.
84. Rubio MP, Correa KM, Ramesh V, MacCollin MM, Jacoby LB, von Deimling A, Gusella JF, Louis DN. 1994. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 54:45-47.
85. Rustgi AK, Xu L, Pinney D, Sterner C, Beauchamp R, Schmidt S, Gusella JF, Ramesh V. 1995. Neurofibromatosis 2 gene in human colorectal cancer. Cancer Genet Cytogenet 84:24-26.
86. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaramam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. 1996. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59:331-342.
87. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM. 1994. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3:885-891.
88. Sanson M, Marineau C, Desmaze C, Lutchman M, Ruttledge M, Baron C, Narod S, Delattre O, Lenoir G, Thomas G, Aurias A, Rouleau GA. 1993. Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Hum Mol Genet 2:1215-1220.
89. Scoles DR, Baser ME, Pulst SM. 1996. A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology 47:544-546.
90. Scoles DR, Chen M, Pulst SM. 2002. Effects of Nf2 missense mutations on schwannomin interactions. Biochem Biophys Res Commun 290:366-374.
91. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. 1995. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227-1231.
92. Sestini R, Vivarelli R, Balestri P, Ammannati F, Montali E, Papi L. 2000. Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene. Hum Genet 107:366-371.
93. Sestini R, Putignano AL, Ammannati F, Papi L. 2005. Detection of rearrangements in the NF2 gene using semi-quantitative multiplex fluorescent PCR. Genet Test 9:14-19.
94. Sheikh HA, Tometsko M, Niehouse L, Aldeeb D, Swalsky P, Finkelstein S, Barnes EL, Hunt JL. 2004. Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence. Am J Surg Pathol 28:101-106.
95. Stangl AP, Wellenreuther R, Lenartz D, Kraus JA, Menon AG, Schramm J, Wiestler OD, von Deimling A. 1997. Clonality of multiple meningiomas. J Neurosurg 86:853-838.
96. Tos M, Stangerup SE, Caye-Thomasen P, Tos T, Thomsen J. 2004. What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg 130:216-220.
97. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800.
98. Tsilchorozidou T, Menko FH, Lalloo F, Kidd A. De Silva R, Thomas H, Smith P, Malcolmson A, Dore J, Madan K, Brown A, Yovos JG, Tsaligopoulos M, Vogiatzis N, Baser ME, Wallace AJ, Evans DG. 2004. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J Med Genet 41:529-534.
99. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. 1999. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59:5995-5998.
100. von Deimling A, Larson J, Wellenreuther R, Stangl AP, van Velthoven V, Warnick R, Tew J Jr, Balko G, Menon AG. 1999. Clonal origin of recurrent meningiomas. Brain Pathol 9:645-650.
101. Wallace AJ, Watson CJ, Oward E, Evans DG, Elles RG. 2004. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test 8:368-380.
102. Watson CJ, Gaunt L, Evans G, Patel K, Harris R, Strachan T. 1993. A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet 2:701-704.
103. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, von Deimling A. 1995. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827-832.
104. Welling Da Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, Linthicum FH, Rogers D, Prior TW. 1996. Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 98:189-193.
105. Welling DB, Akhmametyeva EM, Daniels RL, Lasak JM, Zhu L, Miles-Markley BA, Chang LS. 2000. Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngol Head Neck Surg 123:413-418.
106. Yaegashi S, Sachse R, Ohuchi N, Mori S, Sekiya T. 1995. Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers. Jpn J Cancer Res 86:929-933.
107. Zucman-Rossi J, Legoix P, Der Sarkissian H, Cheret G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, Thomas G. 1998. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 7:2095-2101.